Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | CASP1 | P29466 | 1/20 | 0.82 |
| ▸ | CASP7 | P55210 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmethoxyyangonin SCHEMBL236641 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| Yangonin SCHEMBL1393965 | 0.90 | ALDH1A1 (1.00) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| Yangonin SCHEMBL5584097 | 0.90 | ALDH1A1 (1.00) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL9016266 | 0.86 | MAPT (0.80) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL9016268 | 0.86 | MAPT (0.80) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL9016241 | 0.82 | HIF1A (0.78) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL29584432 | 0.82 | HIF1A (0.78) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL9016238 | 0.82 | HIF1A (0.78) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL19665470 | 0.81 | HIF1A (0.80) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL19665468 | 0.81 | HIF1A (0.80) | ALDH1A1HPGDSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112353791-B | Slip-derived therapeutic compounds and methods of use thereof | 夸利蒂赫布丘蒂克斯公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240374519-A1 | COMPOSITIONS FOR SUPPLEMENTING PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF USE THEREOF | DISRUPTION LABS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| CN-118290377-A | Extraction method of kavalactones for cosmetics | 西安绿天生物技术有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4319722-A1 | COMPOSITIONS FOR SUPPLEMENTING PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF USE THEREOF | Disruption Labs Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023194953-A1 | COMPOSITIONS FOR SUPPLEMENTING PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF USE THEREOF | DISRUPTION LABS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023150361-A1 | KAVA COMPOSITIONS AND METHODS OF MAKING SAME | Botanic Tonics, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230233466-A1 | COMPOSITIONS FOR SUPPLEMENTING PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF USE THEREOF | CORENHANCED TECHNOLOGIES LLC | 2023-07-27 | — | — | US | disclosed |
| CN-116322732-A | Compositions for supplementing products with therapeutic agents and methods of use thereof | 迪斯拉普申实验室公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023067509-A1 | COMPOSITIONS FOR SUPPLEMENTING KOMBUCHA PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF MAKING AND USE THEREOF | DISRUPTION LABS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-4168900-A1 | COMPOSITIONS FOR SUPPLEMENTING PRODUCTS WITH THERAPEUTIC AGENTS AND METHODS OF USE THEREOF | Disruption Labs Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-7199152-B2 | TNF-α production inhibitor comprising kavalactone as an active ingredient | MEIJI DAIRIES CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7199152-B2 | TNF-α production inhibitor comprising kavalactone as an active ingredient | MEIJI DAIRIES CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050069596-A1 | Compositions and methods comprising kava and anti-anxiety compounds | HERBALSCIENCE NUTRACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050037025-A1 | Methods and compositions comprising kava and mate' or theobromine | HERBALSCIENCE NUTRACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1032572-B1 | PYRANONES, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHWABE WILLMAR GMBH & CO (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-6288109-B1 | Pyranones, method for the production and use thereof | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2001-09-11 | — | — | US | disclosed |
| EP-1032572-A2 | PYRANONES, METHOD FOR THE PRODUCTION AND USE THEREOF | Dr. Willmar Schwabe GmbH & Co. (DE) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025716-A9 | PYRANONES, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHWABE WILLMAR GMBH & CO (DE) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999025716-A2 | PYRANONES, METHOD FOR THE PRODUCTION AND USE THEREOF | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1999-05-27 | — | — | WO | disclosed |
| US-5585386-A | MIXTURES FOR APPLICATION TO SKIN OR SCALP | L'OREAL (FR) | 1996-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037025-A1 | Methods and compositions comprising kava and mate' or theobromine | ACHE, TES, KMT5C | ALDH1A1 4389/4885HPGD 1621/4885SMN1; SMN2 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.